Sun Pharma Advanced Research Company: Should You Buy, Hold, or Sell Right Now?
- September 4, 2026
- Posted by: Lakshit Sharma
- Category: Market
SPARC share price Rs 202.54 (NSE), roughly flat today. 52-week range Rs 108 to Rs 289. Q1 FY27 core business remains loss-making despite a low headline PE.
Quick Answer
Sun Pharma Advanced Research Company Ltd (SPARC) share price is trading around Rs 203, roughly 30 percent below its 52-week high of Rs 289 but nearly double its 52-week low of Rs 108. Q1 FY27 revenue was Rs 63.58 crore with a net loss of Rs 20.78 crore, a loss that actually narrowed from a year earlier, but this follows a March 2026 quarter that included an exceptionally large one-off gain of Rs 1,761.34 crore on revenue of Rs 1,855.02 crore, almost certainly a licensing or milestone payment rather than recurring business income. This one-off is why the stock’s headline PE of 4.15 times looks unusually low; the underlying quarterly pharma R&D business remains loss-making, so this ratio should not be read as a conventional value signal.
Sun Pharma Advanced Research Company share price is trading around Rs 203 on the NSE, roughly 30 percent below its 52-week high of Rs 289 but nearly double its 52-week low of Rs 108. Given a large one-off gain that distorts the company’s recent reported earnings, this article explains that distortion clearly before laying out a balanced view on whether SPARC is a stock to buy, a hold, or a sell.
This SPARC stock analysis walks through the Q1 FY27 numbers, the one-off item that inflated trailing earnings, valuation, shareholding pattern and the technical setup, using figures sourced from company disclosures and public filings.
Click Here – Get Free Investment Predictions
About Sun Pharma Advanced Research Company
This background is essential context for SPARC share price discussions. Keep this backdrop in mind when reading the rest of this SPARC share price review. Before deciding on SPARC share price, it helps to understand the underlying business. Sun Pharma Advanced Research Company Ltd. (SPARC) is a pharmaceutical research and development company focused on novel drug delivery systems and new chemical entities, operating as part of the broader Sun Pharmaceutical group ecosystem, though it is a separately listed entity with its own R&D pipeline.
As a pure R&D-focused pharma company, SPARC’s revenue in most quarters is small and tied to licensing fees, milestone payments, or research service income, meaning quarterly results can be lumpy and occasionally include large one-off items when a licensing deal or milestone payment lands, as appears to have happened in the March 2026 quarter.
Sun Pharma Advanced Research Company Share Price Today: Key Levels
This snapshot is the starting point for any SPARC share price discussion. The table below summarises where SPARC share price stands right now against its recent trading range and market value.
| Metric | Value |
|---|---|
| SPARC CMP (NSE) | Rs 202.54 |
| SPARC CMP (BSE) | Rs 202.50 |
| 52-Week High | Rs 289.00 |
| 52-Week Low | Rs 108.00 |
| Market Capitalisation | Approximately Rs 6,572 crore |
SPARC share price has nearly doubled from its 52-week low over the past year, reflecting investor reaction to the large one-off gain reported in the March 2026 quarter, even as the underlying quarterly R&D business remains loss-making.
Check the Univest Screener for Live Stock Data
Sun Pharma Advanced Research Company Financial Performance
These figures anchor the rest of this SPARC share price review. Track this line item closely if you are following SPARC share price closely. The SPARC share price trend is closely tied to how these numbers evolve each quarter. SPARC reported Q1 FY27 (June 2026 quarter) revenue of Rs 63.58 crore, up from a very small base of Rs 18.78 crore a year earlier, with a net loss of Rs 20.78 crore, narrower than the Rs 51.87 crore loss in the same quarter a year earlier. This followed a March 2026 quarter with an exceptional revenue of Rs 1,855.02 crore and net profit of Rs 1,761.34 crore, a scale far beyond the company’s typical quarterly results, almost certainly reflecting a large licensing or milestone payment rather than recurring operating income.
For the full year FY26, the company reported revenue of Rs 1,890.12 crore and net profit of Rs 1,553.2 crore, both figures driven almost entirely by that single large March 2026 quarter item, against a full-year FY25 loss of Rs 342.51 crore on revenue of just Rs 73.56 crore. Investors should treat the FY26 annual figures as reflecting this one-off event rather than a genuine turnaround in the underlying R&D business.
| Period | Revenue | Net Profit | Comment |
|---|---|---|---|
| Q1 FY27 (Jun 2026) | Rs 63.58 crore | Net loss Rs 20.78 crore | Loss narrowed YoY; core business remains loss-making |
| FY26 (full year) | Rs 1,890.12 crore | Rs 1,553.2 crore | Driven almost entirely by a one-off Mar 2026 item, not core operations |
Valuation Check: Is Sun Pharma Advanced Research Company Share Price Expensive?
This context matters for anyone assessing SPARC share price today. It is one of the clearest signals available on SPARC share price today. Any view on SPARC share price should start from these valuation multiples. SPARC share price currently reflects a price to earnings ratio of about 4.15 times trailing earnings, a very steep discount to the broader pharmaceutical sector average of roughly 38 times. However, this low PE is a direct result of the one-off gain inflating the trailing twelve-month earnings base, and should not be interpreted as the stock being conventionally undervalued. The price to book ratio stands near 4.9 times, with return on equity showing 116.01 percent, another figure distorted by the same one-off item.
Debt to equity of 0.42 is moderate. Historically, pharma R&D companies with lumpy, licensing-driven revenue have seen valuation ratios swing dramatically around large one-off items, which is exactly the pattern visible here, making it important to look past the headline PE to the underlying quarterly loss trend.
Technical Signals: What the Chart Shows
Watching SPARC share price over consecutive sessions gives a clearer read than any single print. Price action here often foreshadows the next move in SPARC share price. SPARC share price is currently positioned about 30 percent below its 52-week high of Rs 289 and nearly double its 52-week low of Rs 108, reflecting the market’s strong reaction to the large one-off gain reported earlier in the year. A stock that has re-rated this significantly around a single large licensing or milestone item often sees continued volatility as the market works out how much of that value is durable.
Trading volumes have been notably light in recent sessions, so investors should track SPARC share price alongside any further disclosures about the nature of the one-off item and the underlying R&D pipeline’s progress, rather than reading too much into the current technical levels.
Download the Univest iOS App or Univest Android App to track SPARC’s live price and technical levels.
Shareholding Pattern
This detail is a useful reference point for SPARC share price discussions. Shifts here can influence SPARC share price more than headline news on some sessions. Sun Pharma Advanced Research Company is part of the broader Sun Pharmaceutical group ecosystem as a separately listed pharma R&D entity. A detailed current promoter, FII and DII percentage breakdown was not consistently available across sources at the time of writing and should be verified on the company’s latest exchange filing.
Why Investors Are Watching Sun Pharma Advanced Research Company
- Narrowing quarterly losses: The Q1 FY27 net loss of Rs 20.78 crore was narrower than the year-ago loss, a modest positive sign for the underlying R&D business.
- Association with the Sun Pharma ecosystem: Being part of the broader Sun Pharmaceutical group provides some institutional credibility and potential pipeline support.
- Confirmed large licensing or milestone income: The March 2026 quarter’s exceptional results, whatever their precise source, demonstrate the company’s R&D assets can generate meaningful value when monetised.
- Novel drug delivery focus: SPARC’s specialisation in novel drug delivery systems and new chemical entities targets a differentiated, potentially high-value segment of pharma R&D.
Risks and Factors to Watch
- Core business remains loss-making: Excluding the one-off March 2026 item, SPARC’s quarterly R&D business continues to post losses, and the low headline PE should not be mistaken for genuine undervaluation.
- Lumpy, unpredictable revenue: As a pure R&D company, SPARC’s revenue depends on the timing of licensing deals and milestone payments, which are inherently difficult to predict or model.
- Distorted valuation ratios: Both the PE ratio and return on equity are currently skewed by the one-off gain, making standard valuation comparisons unreliable until this rolls out of trailing figures.
- Pharma R&D pipeline risk: As with any pharmaceutical research company, drug development carries inherent scientific, regulatory and commercial risk with no guarantee of further large monetisation events.
Sun Pharma Advanced Research Company Share Price Target: What the Data Suggests
That is the starting point for anyone assessing SPARC share price. Until then, SPARC share price remains best tracked through live, verified data rather than a single fixed number. SPARC does not have a single widely published, current analyst consensus 12-month share price target consistently available at this time, particularly given the distorted recent earnings base. What the data shows is a pharma R&D company whose core quarterly business remains loss-making despite a large one-off gain earlier in the year.
Investors considering this stock should track the Univest Screener for updates and clarity on the underlying R&D pipeline, and should consult a SEBI-registered investment adviser given the unusual earnings pattern involved.
Sun Pharma Advanced Research Company: Should You Buy, Hold, or Sell Right Now?
There is no shortcut here: SPARC share price needs to be judged against your own plan. This is the core question behind SPARC share price right now. The SPARC buy or sell decision should look past the misleadingly low headline PE to the underlying loss-making core business.
The case for buying: Investors who believe in the underlying R&D pipeline and see the demonstrated ability to generate large licensing income as evidence of future monetisation potential may consider a position, understanding the speculative nature involved.
The case for holding: Existing shareholders who already understand the one-off nature of recent results may prefer to stay invested and watch for further pipeline developments.
The case for waiting: Investors who prefer companies with predictable, recurring earnings may prefer to wait for clearer visibility into the core business’s path to sustainable profitability.
Given the distorted recent earnings, this decision deserves particular care, so consult a SEBI-registered investment adviser before proceeding.
Conclusion
In short, SPARC share price calls for weighing these points together rather than in isolation. Sun Pharma Advanced Research Company share price reflects a pharma R&D business whose headline valuation ratios are distorted by a large one-off gain in the March 2026 quarter, with the underlying quarterly business still loss-making despite narrowing losses. Whether that makes the stock a buy, a hold or a sell right now depends on how you value the R&D pipeline beyond this one-off event. This article is for informational purposes and not a personalised investment recommendation.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Q1. Is SPARC a good stock to buy right now?
Ans. SPARC’s headline PE of 4.15 times looks low, but this is distorted by a large one-off gain in the March 2026 quarter; the underlying Q1 FY27 quarterly business remains loss-making with a Rs 20.78 crore net loss. This suits investors who believe in the R&D pipeline rather than those seeking a conventional value stock.
Q2. Why is SPARC’s PE ratio so low?
Ans. SPARC’s price to earnings ratio of 4.15 times is distorted by an exceptional one-off gain of Rs 1,761.34 crore reported in the March 2026 quarter, almost certainly a licensing or milestone payment, which inflated trailing twelve-month earnings well above what the core R&D business normally generates.
Q3. What is the SPARC share price today?
Ans. Sun Pharma Advanced Research Company share price is trading around Rs 203 on the NSE. The stock’s 52-week high is Rs 289 and its 52-week low is Rs 108.
Q4. What is the SPARC share price target?
Ans. SPARC does not have a single widely published, current analyst consensus 12-month share price target consistently available at this time, given the distorted recent earnings base. Investors should consult a SEBI-registered adviser given the unusual earnings pattern.
Q5. Is SPARC profitable?
Ans. SPARC’s core quarterly business remains loss-making, with a Rs 20.78 crore net loss in Q1 FY27, though this was narrower than a year earlier. The company’s full-year FY26 profit figure was driven almost entirely by a single large one-off item in the March 2026 quarter.
Q6. What does SPARC do?
Ans. Sun Pharma Advanced Research Company is a pharmaceutical research and development company focused on novel drug delivery systems and new chemical entities, operating as part of the broader Sun Pharmaceutical group ecosystem.